% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Blanc:148294,
      author       = {E. Blanc and M. Holtgrewe and A. Dhamodaran and C.
                      Messerschmidt and G. Willimsky$^*$ and T. Blankenstein and
                      D. Beule},
      title        = {{I}dentification and ranking of recurrent neo-epitopes in
                      cancer.},
      journal      = {BMC medical genomics},
      volume       = {12},
      number       = {1},
      issn         = {1755-8794},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2019-02858},
      pages        = {171},
      year         = {2019},
      abstract     = {Immune escape is one of the hallmarks of cancer and several
                      new treatment approaches attempt to modulate and restore the
                      immune system's capability to target cancer cells. At the
                      heart of the immune recognition process lies antigen
                      presentation from somatic mutations. These neo-epitopes are
                      emerging as attractive targets for cancer immunotherapy and
                      new strategies for rapid identification of relevant
                      candidates have become a priority.We carefully screen TCGA
                      data sets for recurrent somatic amino acid exchanges and
                      apply MHC class I binding predictions.We propose a method
                      for in silico selection and prioritization of candidates
                      which have a high potential for neo-antigen generation and
                      are likely to appear in multiple patients. While the
                      percentage of patients carrying a specific neo-epitope and
                      HLA-type combination is relatively small, the sheer number
                      of new patients leads to surprisingly high reoccurence
                      numbers. We identify 769 epitopes which are expected to
                      occur in 77629 patients per year.While our candidate list
                      will definitely contain false positives, the results provide
                      an objective order for wet-lab testing of reusable
                      neo-epitopes. Thus recurrent neo-epitopes may be suitable to
                      supplement existing personalized T cell treatment approaches
                      with precision treatment options.},
      cin          = {L201},
      ddc          = {610},
      cid          = {I:(DE-He78)L201-20160331},
      pnm          = {899 - ohne Topic (POF3-899)},
      pid          = {G:(DE-HGF)POF3-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:31775766},
      pmc          = {pmc:PMC6882202},
      doi          = {10.1186/s12920-019-0611-7},
      url          = {https://inrepo02.dkfz.de/record/148294},
}